Patients demonstrate clear interest in using telehealth to receive mental healthcare as stakeholders await final telehealth guidelines post-pandemic.
Patients continue to utilize telehealth for mental healthcare: Fair Health Read More »
Para ser entrenador personal se puede haber estudiado CAFYD (Actividad Física y el Deporte), haberse especializado con un Máster de entrenamiento personal, haber cursado estudios como Técnico Superior en Animación de Actividades Físicas y Deportivas …
Formación, experiencia y habilidades, las cualidades de un buen entrenador personal Read More »
The layoffs are a result of Sumitomo’s decision announced in April to combine its seven subsidiaries into one company.
Sumitomo Cuts 62 Jobs in NYC Due to Company Consolidation Read More »
The Inflation Reduction Act could put an end to blockbuster runs like that of Merck’s Keytruda, experts told BioSpace. In the meantime, the drug keeps picking up more indications and positive clinical results.
Keytruda Keeps Racking Up Approvals and Clinical Wins in ’23 Read More »
Los pulpos son muy inteligentes, hasta el punto de que en algunos detalles su conducta se parece a la humana. Una investigación reciente ha explorado la cuestión de si su cerebro, pese a lo muy distinto que es del humano, presenta un patrón de sueño similar al del ser hum …
La vida siempre intenta perdurar. Así nos lo demuestra la evolución. Los seres vivos tienden a adaptarse a su medio ambiente para sobrevivir. Cuando la vida evoluciona lo suficiente y adquiere una inteligencia como la humana, entonces puede incluso crear medios artificiales para proteg …
Investing in appropriate outreach as states resume eligibility checks is both humane and economically efficient, argues Jackie Leung, a public health researcher and professor at Linfield University.
Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the approval of its first Clinical Trial Application (CTA) by the Paul-Ehrlich-Institut (PEI) in Germany for KYV101, a novel therapy for the treatment of lupus nephritis (LN).
IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a strategic investment from four investment funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”) who is a leading asset management firm with over $2 billion in managed assets.
IGC Pharma Announces a $3 Million Private Placement of its Common Stock Read More »
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine (NEJM) published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of an investigational use of pirtobrutinib, a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, in adult patients with chronic lymphocytic
